プレシジョン・メディシンの市場規模、シェア、成長分析、技術別、製品別、シーケンス技術別、投与経路別、用途別、最終用途別、地域別-2025～2032年産業予測

プレシジョン・メディシン市場規模は2023年に823億米ドルと評価され、2024年の955億5,000万米ドルから2032年には3,154億2,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは16.1％で成長する展望です。

プレシジョン・メディシンは、同じ病気であっても遺伝や環境の影響などの要因によって身体的反応が異なることを認識することで、医療に革命をもたらしています。このアプローチにより、医療専門家は患者固有の症状や遺伝的体質に基づいて治療をカスタマイズすることができ、治療効果を向上させるとともに、全体的な治療コストを削減できる可能性があります。このセグメントが拡大するにつれ、ゲノミクス研究と遺伝子を標的とした治療法の開発にますます注目が集まっています。さらに、遺伝子検査を伴うコンパニオン診断の人気も上昇傾向にあり、市場の成長をさらに後押ししています。この急成長セグメントは、規制当局による特殊な医薬品の承認の増加によって大きく支えられており、プレシジョン・メディシンは現代の医療戦略にとって不可欠な要素となっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の展望
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主要市場の考察

• 重要成功要因
• 競合の程度
• 主要投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 使用事例

プレシジョン・メディシン市場規模：技術別&CAGR（2025～2032年）

• 市場概要
• バイオインフォマティクス
• ビッグデータ分析
• 創薬
• 遺伝子配列分析
• コンパニオン診断
• その他

プレシジョン・メディシン市場規模：製品別&CAGR（2025～2032年）

• 市場概要
• 消耗品
• 機器
• サービス

プレシジョン・メディシン市場規模：シーケンス技術別&CAGR（2025～2032年）

• 市場概要
• 合成によるシーケンス
• イオン半導体シーケンス
• ライゲーションによるシークエンシング
• ピロシークエンス
• 単一分子リアルタイムシーケンス
• 連鎖終結シーケンス
• ナノポアシーケンス

プレシジョン・メディシン市場規模：投与経路別&CAGR（2025～2032年）

• 市場概要
• 経口
• 注射剤
• 薬剤別
• アレクチニブ
• オシメルチニブ
• メポリズマブ
• アリピプラゾールラウロキシル
• その他

プレシジョン・メディシン市場規模：用途別&CAGR（2025～2032年）

• 市場概要
• 中枢神経系
• 免疫学
• 腫瘍学
• 呼吸器
• その他

プレシジョン・メディシン市場規模：最終用途別&CAGR（2025～2032年）

• 市場概要
• 診断会社
• 製薬会社
• 医療IT企業
• その他

プレシジョン・メディシン市場規模&CAGR（2025～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他の中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主要市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

    主要企業プロファイル

    • Hoffmann-La Roche Ltd.（スイス）
    • Novartis AG（スイス）
    • Pfizer Inc.（米国）
    • Bristol Myers Squibb（米国）
    • AstraZeneca（英国）
    • Almac Group Ltd.（英国）
    • Gilead Sciences, Inc.（米国）
    • AbbVie Inc.（米国）
    • Eli Lilly and Company（米国）
    • GlaxoSmithKline plc（英国）
    • Ab-BIoTics Sa（米国）
    • Johnson & Johnson（米国）
    • Merck KGaA（ドイツ）
    • Amgen, Inc.（米国）

結論と提言

Precision Medicine Market size was valued at USD 82.3 billion in 2023 and is poised to grow from USD 95.55 billion in 2024 to USD 315.42 billion by 2032, growing at a CAGR of 16.1% during the forecast period (2025-2032).

Precision medicine is revolutionizing healthcare by recognizing that individuals with the same illness can have varied physical responses due to factors like genetics and environmental influences. This approach allows healthcare professionals to tailor treatments based on a patient's unique symptoms and genetic makeup, improving therapeutic effectiveness while potentially lowering overall treatment costs. As the field expands, there is an increasing focus on genomics research and the development of genetically targeted therapies. Additionally, the popularity of companion diagnostics that involve genetic testing is on the rise, further propelling market growth. This burgeoning sector is significantly supported by an increase in specialized drug approvals from regulatory bodies, positioning precision medicine as a vital component of modern healthcare strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Precision Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Precision Medicine Market Segments Analysis

Global Precision Medicine Market is segmented by Technology, Product, Sequencing Technology, Route of Administration, Application, End-Use and region. Based on Technology, the market is segmented into Bioinformatics, Big Data Analytics, Drug Discovery, Gene Sequencing, Companion Diagnostics and Others. Based on Product, the market is segmented into Consumables, Instruments and Services. Based on Sequencing Technology, the market is segmented into Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing, Chain Termination Sequencing and Nanopore Sequencing. Based on Route of Administration, the market is segmented into Oral, Injectable, By Drugs, Alectinib, Osimertinib, Mepolizumab, Aripiprazole Lauroxil and Others. Based on Application, the market is segmented into CNS, Immunology, Oncology, Respiratory and Others. Based on End-Use, the market is segmented into Diagnostic Companies, Pharmaceutical Companies, Healthcare IT companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Precision Medicine Market

The Precision Medicine market is primarily driven by the comprehensive diagnostic assessments that analyze a patient's genetic makeup for variations, mutations, and individual differences. This tailored approach to treatment is increasingly supported by the growing accessibility of prenatal and cancer screening tests, as well as direct-to-consumer genetic tests. These developments are stimulating the demand for genetic testing services, which enables healthcare providers to create personalized treatment plans based on specific genetic information. Consequently, the market for Precision Medicine continues to expand as more patients seek customized healthcare solutions that address their unique genetic profiles.

Restraints in the Precision Medicine Market

The Precision Medicine market faces notable restraints due to significant privacy and security issues associated with the extensive collection and analysis of personal genetic and health data. The handling of such sensitive information raises the risk of breaches and other forms of misuse, which can jeopardize patient trust and confidence in these medical advancements. As concerns mount over the protection of individual data, the adoption of precision medicine solutions may be hindered, resulting in increased skepticism among potential patients and healthcare providers alike. Addressing these privacy challenges is crucial for fostering a more favorable environment for the growth of the Precision Medicine market.

Market Trends of the Precision Medicine Market

The precision medicine market is experiencing a transformative shift, driven by the integration of genetic insights and targeted therapies into healthcare frameworks. Advances in DNA sequencing and molecular profiling are pivotal, enabling clinicians to craft personalized treatment regimens tailored to an individual's unique genetic makeup. This trend not only enhances diagnostic accuracy but also optimizes treatment efficacy, resulting in improved patient outcomes. As healthcare shifts from a one-size-fits-all model to a more individualized approach, the demand for precision medicine continues to grow, highlighting its crucial role in the evolution of contemporary medicine and paving the way for innovative health solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Precision Medicine Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Bioinformatics
• Big Data Analytics
• Drug Discovery
• Gene Sequencing
• Companion Diagnostics
• Others

Global Precision Medicine Market Size by Product & CAGR (2025-2032)

• Market Overview
• Consumables
• Instruments
• Services

Global Precision Medicine Market Size by Sequencing Technology & CAGR (2025-2032)

• Market Overview
• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Sequencing by Ligation
• Pyrosequencing
• Single Molecule Real Time Sequencing
• Chain Termination Sequencing
• Nanopore Sequencing

Global Precision Medicine Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• By Drugs
• Alectinib
• Osimertinib
• Mepolizumab
• Aripiprazole Lauroxil
• Others

Global Precision Medicine Market Size by Application & CAGR (2025-2032)

• Market Overview
• CNS
• Immunology
• Oncology
• Respiratory
• Others

Global Precision Medicine Market Size by End-Use & CAGR (2025-2032)

• Market Overview
• Diagnostic Companies
• Pharmaceutical Companies
• Healthcare IT companies
• Others

Global Precision Medicine Market Size & CAGR (2025-2032)

• North America (Technology, Product, Sequencing Technology, Route of Administration, Application, End-Use)
  • US
  • Canada
• Europe (Technology, Product, Sequencing Technology, Route of Administration, Application, End-Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Product, Sequencing Technology, Route of Administration, Application, End-Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Product, Sequencing Technology, Route of Administration, Application, End-Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Product, Sequencing Technology, Route of Administration, Application, End-Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac Group Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ab-Biotics Sa (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations